Portal de Periódicos da CAPES

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

2022; Elsevier BV; Volume: 140; Issue: 5 Linguagem: Inglês

10.1182/blood.2022016147

1528-0020

Carsten Utoft Niemann, Caspar da Cunha‐Bang, Marie Helleberg, Sisse Rye Ostrowski, Christian Brieghel,

Chronic Lymphocytic Leukemia Research

Abstract Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.